"Dupilumab Significantly Improves Atopic Dermatitis In Asian, Black And White Patients" - Abigail Sutton
Dupilumab significantly improved atopic dermatitis signs, symptoms and quality of life in Asian, black and white patients, according to researchers at the Icahn School of Medicine at Mount Sinai. “Trends in this analysis suggest that dupilumab 300 mg [weekly] may provide incremental benefits over the regimen in black/African American patients; however, interpretation is limited by the small sample size of the black/African American cohort and variations in mean body weight between racial subgroups,” said Andrew Alexis, MD, PhD, director of the Skin of Color Center at Mount Sinai and chair of the department of dermatology at Mount Sinai St. Luke’s and Mount Sinai West. He added, “Filaggrin loss-of-function mutations, which lead to deficiency of the structural protein filaggrin and resulting skin barrier defects, have been identified as a major predisposing factor for the development of [atopic dermatitis] in Europeans and Asians.”
— Andrew Alexis, MD, MPH, Associate Professor, Dermatology, Icahn School of Medicine at Mount Sinai, Director, The Skin of Color Center at Mount Sinai, Site Chair, Department of Dermatology, Mount Sinai St. Luke’s-Mount Sinai West
Mount Sinai Researchers Identify Key Gut Sensor That Regulates Digestion and Immunity
Mar 24, 2025 View All Press Releases
New Insights Revealed On Tissue-Dependent Roles of JAK Signaling in Inflammation
Dec 21, 2023 View All Press Releases
New RNA-based Therapy Combats Melanoma in Mouse Models
Jul 27, 2023 View All Press Releases
